Related Experiment Video
Updated: Jul 4, 2025

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Causal Effects of COVID-19 on the Risk of Thrombosis: A Two-Sample Mendel Randomization Study
Zhengran Li1,2, Minghui Zeng3, Tong Wu4
1The Second Clinical Medicine School, Southern Medical University, Guangzhou, Guangdong, China.
Insights
This study reveals how COVID-19 impacts thrombosis biomarkers. Lowering tissue factor pathway inhibitor (TFPI) and interleukin-1 receptor type 1 (IL-1R1) suggests a causal link between COVID-19 and increased thrombosis risk.
Area of Science:
- Biomedical Science
- Genetics
- Epidemiology
Background:
- The link between Coronavirus disease 2019 (COVID-19) and thrombosis is established, yet the underlying biomolecular mechanisms remain largely unknown.
- Investigating the causal relationship between COVID-19 and thrombotic biomarkers is crucial for understanding disease pathogenesis and developing targeted therapies.
Purpose of the Study:
- To investigate the causal relationship between COVID-19 and 20 key thrombotic biomarkers using Mendelian randomization.
- To elucidate the biomolecular mechanisms linking COVID-19 infection to thrombotic events.
Main Methods:
- Two-sample Mendelian randomization (MR) was employed to assess the effect of COVID-19 on thrombotic biomarkers.
- Causality was estimated using inverse variance weighting, with sensitivity analyses performed using weighted median, MR-Egger regression, and MR-PRESSO methods.
- Results were corrected for multiple testing using the false discovery rate (FDR) with the Benjamin and Hochberg method.
Main Results:
- COVID-19 was associated with significantly lower levels of tissue factor pathway inhibitor (TFPI) and interleukin-1 receptor type 1 (IL-1R1), nearly doubling the odds of thrombosis.
- Hospitalized cases showed reduced levels of plasminogen activator, tissue type (tPA) and P-selectin glycoprotein ligand 1 (PSGL-1), while severe cases exhibited higher mean platelet volume (MPV) and lower platelet count.
- These biomarker changes, particularly in TFPI, tPA, IL-1R1, MPV, and platelet count, suggest an elevated risk of thrombosis in COVID-19 patients.
Conclusions:
- TFPI, IL-1R1, and seven other indicators provide causal insights into the pathogenesis of COVID-19 and thrombosis.
- This study provides robust evidence that COVID-19 causally influences thrombosis at the biomolecular level.
- Findings highlight potential therapeutic targets for managing thrombotic complications in COVID-19.
Background:
Coronavirus disease 2019 (COVID-19) and thrombosis are linked, but the biomolecular mechanism is unclear. We aimed to investigate the causal relationship between COVID-19 and thrombotic biomarkers.
Methods:
We used two-sample Mendelian randomization (MR) to assess the effect of COVID-19 on 20 thrombotic biomarkers. We estimated causality using inverse variance weighting with multiplicative random effect, and performed sensitivity analysis using weighted median, MR-Egger regression and MR Pleiotropy Residual Sum and Outlier (MR-PRESSO) methods. All the results were examined by false discovery rate (FDR) with the Benjamin and Hochberg method for this correction to minimize false positives. We used R language for the analysis.
Results:
All COVID-19 classes showed lower levels of tissue factor pathway inhibitor (TFPI) and interleukin-1 receptor type 1 (IL-1R1). COVID-19 significantly reduced TFPI (odds ratio [OR] = 0.639, 95% confidence interval [CI]: 0.435-0.938) and IL-1R1 (OR = 0.603, 95% CI = 0.417-0.872), nearly doubling the odds. We also found that COVID-19 lowered multiple coagulation factor deficiency protein 2 and increased C-C motif chemokine 3. Hospitalized COVID-19 cases had less plasminogen activator, tissue type (tPA) and P-selectin glycoprotein ligand 1 (PSGL-1), while severe cases had higher mean platelet volume (MPV) and lower platelet count. These changes in TFPI, tPA, IL-1R1, MPV, and platelet count suggested a higher risk of thrombosis. Decreased PSGL-1 indicated a lower risk of thrombosis.
Conclusion:
TFPI, IL-1R, and seven other indicators provide causal clues of the pathogenesis of COVID-19 and thrombosis. This study demonstrated that COVID-19 causally influences thrombosis at the biomolecular level.
More Related Videos
09:19In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Causality in Epidemiology
Criteria for Causality: Bradford Hill Criteria - II
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Randomized Experiments
Simple randomization
Simple...
Regression Toward the Mean
Confounding in Epidemiological Studies